Mohamad Takwa

Glycolink offers a novel class of hydrogel, free from synthetic components, easy-to-prepare, containing just two natural ingredients from sustainable sources and with no need for any chemical modification. Our hydrogel can be used in virtually any industrial application or R&D that needs a water-based matrix. The standard gel can be engineered to contain functional bioactive compounds as needed. Using a proprietary approach to hydrogel formation developed at the KTH Royal Institute of Technology in Sweden, this new material is environmentally friendly and has an extremely small waste footprint.

Spermosens goal is to improve male fertility diagnostics and treatment through the introduction of ground breaking products. Spermosens first patented product JUNO-Checked measures the binding capacity between sperm and egg cell, which is a prerequisite for natural fertilization. The results are deemed to be able to help doctors choose the appropriate treatment method, which contributes to more successful IVF treatments, reduced suffering, and increased quality of life. The WHO estimates that more than 48 million couples are affected by infertility, half of which is caused in whole or in part by a male factor. The companys shares are listed on Spotlight Stock market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com

Capitral is a seed investment company with roots in the academic world and a passion for social responsibility. Our goal is to build bridges between science and business to make ground-breaking ideas accessible to the ones who need it.

Glycolink offers a novel class of hydrogel, free from synthetic components, easy-to-prepare, containing just two natural ingredients from sustainable sources and with no need for any chemical modification. Our hydrogel can be used in virtually any industrial application or R&D that needs a water-based matrix. The standard gel can be engineered to contain functional bioactive compounds as needed. Using a proprietary approach to hydrogel formation developed at the KTH Royal Institute of Technology in Sweden, this new material is environmentally friendly and has an extremely small waste footprint.

Thioredoxin Systems AB is a biotechnology company developing a novel antibiotic regimen against pathogenic bacteria. EbsArgent is a patented combination of ebselen and silver, capable of functioning as an antiseptic, antibacterial in food production, and as a medicinal product. With its versatility and ability to act on a wide range of multi-drug resistant bacteria, it is among the most promising antibiotic regimen under development today.

Epigenica is a life sciences technology company at the forefront of innovations in epigenetic research. The company’s EpiFinder platform enables researchers to perform comprehensive epigenetic studies at unprecedented speed, scalability, and affordability. Epigenica is building a portfolio of products based on the EpiFinder platform to offer comprehensive high-throughput profiling at different depths of detail with an array of possible starting materials. The platform is powered by the company’s patented and proprietary high-throughput, multiplex, quantitative ChIP-seq technology (hmqChIP), the first commercial kit of its kind. With the advantages of the EpiFinder platform, Epigenica is helping researchers advance biomedical research, drug discovery and development, precision medicine, diagnostics, and therapeutics for aging and longevity.

Spermosens goal is to improve male fertility diagnostics and treatment through the introduction of ground breaking products. Spermosens first patented product JUNO-Checked measures the binding capacity between sperm and egg cell, which is a prerequisite for natural fertilization. The results are deemed to be able to help doctors choose the appropriate treatment method, which contributes to more successful IVF treatments, reduced suffering, and increased quality of life. The WHO estimates that more than 48 million couples are affected by infertility, half of which is caused in whole or in part by a male factor. The companys shares are listed on Spotlight Stock market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com

Thyrolytics AB develops a first-of-its-kind diagnostic device for measuring serum levels of free T4 and T3. In contrast to the convectional diagnosis methods for thyroid disorders, our technology implies one-step direct measurement of the fT3 and fT4 concentrations.